Wordt geladen...
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
Background This phase I study evaluated the pharmacokinetics and pharmacodynamics of CEP-11981, an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, in patients with advanced, relapsed, or refractory solid tumors. Methods Oral CEP-11981 dose escalations followed a modified Fi...
Bewaard in:
| Gepubliceerd in: | Invest New Drugs |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer US
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4226840/ https://ncbi.nlm.nih.gov/pubmed/25152243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0147-9 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|